Hitachi Chemical has recently obtained the license for Accellta's latest media which is devoid of human/animal derived components and comprised only of artificially synthesized substances, offering a high level of safety that is key to the success of regenerative medicine.

Accellta granted exclusive worldwide rights for micro-carrier free stem cells suspension culture to STEMCELL Technologies.

Accellta has granted worldwide non-exclusive rights to Ajinomoto Co. Inc. for manufacturing and distribution of proprietary cell culture medium and ancillary products and methods.

Accellta has granted worldwide non-exclusive rights to EMD Millipore for manufacturing and distribution of proprietary cell culture medium and ancillary products and methods.